pubrio
WuXi Biologics/药明生物 logo

WuXi Biologics/药明生物

Public
wuxibiologics.com
Pharmaceuticals2,900+ employeesFounded 2010🇨🇳 China

Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

Founded
2010
Employees
2,900+
Industry
Pharmaceuticals
Company type
Public Company
Stock
hkse: 2269.HK
Headquarters
🇨🇳108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092, Wuxi, Jiangsu 214092, Cn (+9)
Specialties
PharmaceuticalsBiotechnologyHealthcare

Expansion Intelligence

NEW · only on Pubrio

We're tracking WuXi Biologics/药明生物's market expansion

Global expansion

Live
Stages
ExploringInvestingLandingOperating

Activity pulse

New Footprint activity — 9 fresh signals just appeared.

Last 90 days
Hiring
5-33%
Hiring
Marketing & PR
0
No activity
Product & Tech
1Ended
Product launch
+2more categoriesLocked
3 of 5 shown
Good to know

Frequently Asked Questions Regarding WuXi Biologics/药明生物

Quick answers about WuXi Biologics/药明生物's business, markets, and growth signals.

Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

Start Journey Image
pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​

© 2026 Pubrio. All rights reserved.